Halozyme Therapeutics's Earnings: A Preview
Halozyme Therapeutics's Earnings: A Preview
Halozyme Therapeutics (NASDAQ:HALO) releases its next round of earnings this Tuesday, February 23. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
滷酶治療學(納斯達克：光暈)將於2月23日(星期二)公佈下一輪財報。在Benzinga公司第四季度收益報告的基本指南中獲得最新的預測。
Net Income, Earnings, And Earnings Per Share
淨收入、收益和每股收益
Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.
收益和每股收益是衡量盈利能力的有用指標。總收入，也稱為淨收入，等於總收入減去總支出。淨利潤除以流通股總數得出每股收益。
Earnings And Revenue
收入和收入
Halozyme Therapeutics EPS is expected to be around $0.53, according to sell-side analysts. Sales will likely be near $120.16 million. In the same quarter last year, Halozyme Therapeutics reported EPS of $0.24 on revenue of $53.66 million.
據賣方分析師稱，Halozyme治療公司的每股收益預計在0.53美元左右。銷售額可能接近1.2016億美元。去年同一季度，Halozyme治療公司報告每股收益為0.24美元，營收為5366萬美元。
What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter?
分析師的預期和收益驚喜是什麼？為什麼它們很重要？
Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.
負責該公司業務的分析師將每季度發佈對其收入和每股收益的前瞻性估計。把每個分析師對一家公司一個季度的每股收益和營收預測加在一起，得出的是“共識估計”。一家公司公佈的收益或收入高於或低於普遍預期，這被稱為“收益驚喜”，可能會使股價大幅波動。
If the company were to match the consensus estimate, earnings would be up 320.83%. Revenue would be up 123.91% from the year-ago period. Here is how the company's reported EPS has stacked up against analyst estimates in the past:
如果該公司達到普遍預期，收益將增長320.83%。營收將比去年同期增長123.91%。以下是該公司過去公佈的每股收益與分析師預期的對比情況：
| Quarter | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | 0.20 | 0.25 | -0.02 | -0.15 |
| EPS Actual | 0.25 | 0.19 | -0.04 | -0.24 |
| Revenue Estimate | 60.91 M | 66.68 M | 42.96 M | 56.93 M |
| Revenue Actual | 65.32 M | 55.22 M | 25.35 M | 53.66 M |
| 季度 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2020 |
|---|---|---|---|---|
| 每股收益預估 | 0.20 | 0.25 | -0.02 | -0.15 |
| 實際每股收益 | 0.25 | 0.19 | -0.04 | -0.24 |
| 收入預估 | 60.91 M | 66.68 M | 42.96 M | 56.93 M |
| 實際收入 | 65.32 M | 55.22 M | 25.35 M | 53.66 M |
Stock Performance
股票表現
Shares of Halozyme Therapeutics were trading at $49.68 as of February 19. Over the last 52-week period, shares are up 139.13%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.
截至2月19日，Halozyme Treeutics的股價為49.68美元。在過去52周內，股價上漲了139.13%。考慮到這些回報總體上是積極的，長期股東應該對此次收益發布感到滿意。
Do not be surprised to see the stock move on comments made during its conference call. Halozyme Therapeutics is scheduled to hold the call at 16:30:00 ET and can be accessed here.
如果看到該股在電話會議期間發表的評論出現波動，不要感到驚訝。Halozyme Treeutics計劃在美國東部時間16：30：00舉行電話會議，可以訪問這裏.
譯文內容由第三人軟體翻譯。